Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct 18;6(10):e012795.
doi: 10.1136/bmjopen-2016-012795.

OPTIMUM: a protocol for a multicentre randomised controlled trial comparing Out Patient Talc slurry via Indwelling pleural catheter for Malignant pleural effusion vs Usual inpatient Management

P Sivakumar  1   2 , A Douiri  2 , A West  1 , D Rao  3 , G Warwick  4 , T Chen  2 , L Ahmed  1   2
Affiliations
Randomized Controlled Trial

OPTIMUM: a protocol for a multicentre randomised controlled trial comparing Out Patient Talc slurry via Indwelling pleural catheter for Malignant pleural effusion vs Usual inpatient Management

P Sivakumar et al. BMJ Open. .

Erratum in

  • Correction.
    [No authors listed] [No authors listed] BMJ Open. 2016 Nov 14;6(11):e012795corr1. doi: 10.1136/bmjopen-2016-012795corr1. BMJ Open. 2016. PMID: 28186953 Free PMC article. No abstract available.

Abstract

Introduction: The development of malignant pleural effusion (MPE) results in disabling breathlessness, pain and reduced physical capability with treatment a palliative strategy. Ambulatory management of MPE has the potential to improve quality of life (QoL). The OPTIMUM trial is designed to determine whether full outpatient management of MPE with an indwelling pleural catheter (IPC) and pleurodesis improves QoL compared with traditional inpatient care with a chest drain and talc pleurodesis. OPTIMUM is currently open for any centres interested in collaborating in this study.

Methods and analysis: OPTIMUM is a multicentre non-blinded randomised controlled trial. Patients with a diagnosis of MPE will be identified and screened for eligibility. Consenting participants will be randomised 1:1 either to an outpatient ambulatory pathway using IPCs and talc pleurodesis or standard inpatient treatment with chest drain and talc pleurodesis as per British Thoracic Society guidelines. The primary outcome measure is global health-related QoL at 30 days measured using the EORTC QLQ-C30 questionnaire. Secondary outcome measures include breathlessness and pain measured using a 100 mm Visual Analogue Scale and health-related QoL at 60 and 90 days. A sample size of 142 patients is needed to demonstrate a clinically significant difference of 8 points in global health status at 30 days, for an 80% power and a 5% significance level.

Ethics and dissemination: The study has been approved by the NRES Committee South East Coast-Brighton and Sussex (reference 15/LO/1018). The trial results will be published in peer-reviewed journals and presented at scientific conferences.

Trial registration numbers: UKCRN19615 and ISRCTN15503522; Pre-results.

Keywords: Indwelling pleural catheter; Malignant pleural effusion; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Trial pathway for the indwelling pleural catheter group. CXR, Chest X-ray; USS, ultrasound scan; IPC, indwelling pleural catheter; QoL, quality of life.
Figure 2
Figure 2
Sites of thoracic ultrasound to assess for pleural apposition.
Figure 3
Figure 3
Trial pathway for the usual care group. CXR, chest X-ray; USS, ultrasound scan; IPC, indwelling pleural catheter; QoL, quality of life.
See this image and copyright information in PMC

References

    1. Muduly D, Deo S, Subi Ts et al. . An update in the management of malignant pleural effusion. Indian J Palliat Care 2011;17:98–103. 10.4103/0973-1075.84529 - DOI - PMC - PubMed
    1. Rahman NM, Ali NJ, Brown G et al. . Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65(Suppl 2):ii54–60. 10.1136/thx.2010.137018 - DOI - PubMed
    1. Clive AO, Kahan BC, Hooper CE et al. . Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014;69:1098–104. 10.1136/thoraxjnl-2014-205285 - DOI - PMC - PubMed
    1. Roberts ME, Neville E, Berrisford RG et al. . Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65(Suppl 2):ii32–40. 10.1136/thx.2010.136994 - DOI - PubMed
    1. Davies HE, Mishra EK, Kahan BC et al. . Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012;307:2383–9. 10.1001/jama.2012.5535 - DOI - PubMed

Publication types

MeSH terms

Associated data